MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
2018 · Scientific Reports · 45 citations
https://doi.org/10.1038/s41598-018-20326-z
M
Masahiro Tabata
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
340
Papers
5.9K
Citations
39
h-index
123
i10-index
Masahiro Tabata is an academic researcher from Okayama University Hospital. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 39, co-authored 289 publications.
ORCID: 0000-0002-0008-2275Papers by this author
worksSHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve <i>ALK-, ROS1-</i> , or <i>EGFR</i> -altered Non–small Cell Lung Cancer
2021 · Molecular Cancer Therapeutics · 15 citations
https://doi.org/10.1158/1535-7163.mct-20-0965
Demand for weekend outpatient chemotherapy among patients with cancer in Japan
2020 · Supportive Care in Cancer · 6 citations
https://doi.org/10.1007/s00520-020-05575-x
Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines
2025 · Lung Cancer · 3 citations
https://doi.org/10.1016/j.lungcan.2025.108415
Capsular impingement as a source of pain following bipolar hip arthroplasty.
1991 · PubMed · 0 citations
https://doi.org/10.1016/s0883-5403(11)80012-4
Patients’ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.10048598
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat